Cardiovascular Today—April 9, 2026

This week’s Cardiovascular update highlights regulatory activity, clinical data readouts, device innovation, and expanding trial infrastructure across structural heart and cardiometabolic care.

In Today’s Newsletter

Dive deeper

🫀 BioCardia seeks FDA pathway talks for CardiAMP in ischemic HFrEF [1] [US • 02 Apr 2026]

https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=257
Context: CardiAMP (BioCardia; autologous cell therapy) is being studied in ischemic chronic heart failure with reduced ejection fraction, under FDA Breakthrough designation.
Key point: BioCardia said it submitted CardiAMP HF trial data and requested an FDA meeting to discuss a potential accelerated approval pathway.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Esperion highlights new CLEAR Outcomes analyses for bempedoic acid [2] [US • 01 Apr 2026]

https://www.dicardiology.com/content/esperion-presents-new-data-clear-outcomes-highlighting-value-bempedoic-acid-acc26
Context: At ACC.26, Esperion presented post-hoc CLEAR Outcomes analyses on ischemic stroke and cardiovascular outcomes in patients with autoimmune or inflammatory disease.
Key point: The company reported a 22% lower risk of ischemic stroke versus placebo in statin-intolerant patients, and similar benefit in the autoimmune or inflammatory disease subgroup.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Iterative Health, US Heart & Vascular expand community-based trial infrastructure [3] [US • 02 Apr 2026]

https://www.dicardiology.com/content/iterative-health-us-heart-vascular-partner-advance-community-based-cardiovascular-research
Context: US Heart & Vascular research sites will join Iterative Health’s site network, which the companies said spans more than 100 sites across three continents.
Key point: The partnership is designed to bring centralized research operations and more trial access into community cardiology settings.
Implication: Signals pipeline investment and modality expansion.

🔔 Medtronic reports ALERT gains with AI-enabled structural heart notifications [4] [US • 07 Apr 2026]

https://cardiovascularnews.com/electronic-notifications-improve-timely-evaluation-of-structural-heart-disease/
Context: ALERT used Tempus Next across five US health systems, 35 hospitals, 765 clinicians, and 2,016 echocardiograms to identify AS or MR patients lacking a treatment plan.
Key point: Electronic clinician notifications improved timely evaluation and treatment, including a 40% relative increase in valve intervention and a 27% increase in multidisciplinary heart team evaluations at 90 days.
Implication: May expand screening, initiation, and follow-up at scale.

🫁 TRiCares wins US IDE approval for pivotal Topaz TTVR trial [5] [US • 07 Apr 2026]

https://cardiovascularnews.com/topaz-ttvr-system-given-green-light-for-us-ide-trial/
Context: The randomized pivotal trial will run at up to 75 sites in the US, Canada, and select European centers in patients with severe or greater tricuspid regurgitation at increased operative risk.
Key point: TRiCares said the FDA granted IDE approval for the Topaz transcatheter tricuspid valve replacement study, enabling US pivotal trial start-up.
Implication: May influence prescriber choice and payer reviews pending full data.

🩺 Medtronic launches EMBRACE, pairing renal denervation with staged PCI [6] [US/EU/Asia • 02 Apr 2026]

https://cardiovascularnews.com/trial-of-renal-denervation-and-staged-pci-in-patients-with-multivessel-coronary-disease-and-hypertension-launches/
Context: EMBRACE will enroll 1,000 patients at 55 sites in up to 20 countries, comparing Symplicity Spyral renal denervation plus staged PCI versus staged PCI alone.
Key point: Medtronic launched a randomized multicenter outcomes trial in multivessel coronary disease and uncontrolled hypertension, with a two-year primary endpoint assessment.
Implication: May influence prescriber choice and payer reviews pending full data.

❤️ Edwards shares updated TRISCEND II crossover analysis for Evoque [7] [US • 07 Apr 2026]

https://cardiovascularnews.com/latest-data-from-triscend-ii-trial-look-at-crossover-patients-treated-with-evoque-system/
Context: Updated TRISCEND II data were presented at ACC.26 and followed earlier 18-month findings presented at ESC 2025.
Key point: Edwards said the Evoque TTVR system showed sustained near elimination of tricuspid regurgitation, improved health status and quality of life, and lower all-cause mortality when crossover was accounted for.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Lupin gains US approval for generic dapagliflozin tablets [8] [US • 07 Apr 2026]

https://www.prnewswire.com/news-releases/lupin-announces-the-approval-of-dapagliflozin-tablets-in-the-united-states-302736136.html
Context: Lupin’s dapagliflozin tablets, 5 mg and 10 mg, were approved as bioequivalent to Farxiga for the labeled indications.
Key point: Lupin received US FDA approval for its abbreviated new drug application for dapagliflozin tablets in the United States.
Implication: Introduces competition that may affect pricing and formulary access.

Why it matters

Structural heart remains a dense news area, with Medtronic, TRiCares, and Edwards all advancing diagnosis or treatment pathways for valve disease.
Cardiovascular trial execution is moving beyond academic centers, with Iterative Health and US Heart & Vascular pushing community-site capacity.
Device makers continue to frame earlier intervention and workflow automation as ways to reduce undertreatment and care disparities.
Cardiometabolic competition is also rising, with new outcomes analyses for bempedoic acid and generic entry for dapagliflozin.
Regulatory progress is uneven but active, from IDE trial approvals to pre-submission FDA discussions on novel cell therapy.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is BioCardia asking the FDA to review for CardiAMP?

BioCardia said it submitted CardiAMP HF clinical data and requested an FDA meeting to discuss a possible accelerated approval pathway for the CardiAMP System in ischemic HFrEF under Breakthrough designation [1].

What did Esperion report from CLEAR Outcomes?

Esperion highlighted post-hoc analyses showing a 22% reduction in ischemic stroke risk with bempedoic acid versus placebo in statin-intolerant patients, plus similar benefit in participants with autoimmune or inflammatory disease [2].

What does the Iterative Health and US Heart & Vascular deal actually change?

USHV research sites will join Iterative Health’s broader site network and gain centralized operational support, with the aim of expanding access to cardiovascular trials in community settings [3].

Why does the ALERT study matter for Medtronic and structural heart care?

The study suggests AI-enabled electronic alerts can speed evaluation and treatment for significant AS and MR, including higher rates of valve intervention and heart team review within 90 days [4].

What is new about TRiCares Topaz and Edwards Evoque?

TRiCares received IDE approval to begin a pivotal Topaz TTVR trial in North America and Europe [5]. Edwards, meanwhile, reported updated TRISCEND II findings supporting sustained benefit for Evoque in tricuspid regurgitation [7].

What is the significance of Lupin’s dapagliflozin approval?

Lupin’s product was approved as bioequivalent to Farxiga in the US, which adds a generic entrant in dapagliflozin and could affect pricing and access over time [8].

Entities / Keywords

BioCardia, CardiAMP, CardiAMP HF, ischemic HFrEF, cell therapy
Esperion, bempedoic acid, NEXLETOL, CLEAR Outcomes, ischemic stroke
Iterative Health, US Heart & Vascular, USHV, community-based cardiovascular research
Medtronic, Tempus Next, ALERT, aortic stenosis, mitral regurgitation, TAVI
TRiCares, Topaz, TTVR, tricuspid regurgitation, IDE
Medtronic, Symplicity Spyral, EMBRACE, renal denervation, PCI, multivessel coronary disease
Edwards Lifesciences, Evoque, TRISCEND II, transcatheter tricuspid valve replacement
Lupin, dapagliflozin, Farxiga, generic, ANDA, US FDA